
Agenus Highlights Phase II Data Showing Durable Survival and Immune Reprogramming in PD-1 Refractory Gastroesophageal Cancer
Agenus highlights durable survival and immune reprogramming in PD-1 refractory gastroesophageal cancer with Botensilimab combo Agenus Inc., a company focused on advancing immuno-oncology innovation, has reported new clinical findings from…












